The fucosylation index of serum α-fetoprotein as useful prognostic factor in patients with hepatocellular carcinoma in special reference to chronological changes

被引:31
作者
Aoyagi, Y
Mita, Y
Suda, T
Kawai, K
Kuroiwa, T
Igarashi, M
Kobayashi, M
Waguri, N
Asakura, H
机构
[1] Niigata Univ, Grad Sch Med & Dent Sci, Course Mol & Cellular Med, Dept Mol Genet,Dept Cellular Funct,Div Hepatobili, Niigata 9518122, Japan
[2] Niigata Univ, Grad Sch Med & Dent Sci, Course Mol & Cellular Med, Dept Mol Genet,Dept Cellular Funct,Div Gastroente, Niigata 9518122, Japan
关键词
alpha-fetoprotein; fucosylation index; hepatocellular carcinoma; prognostic factor; survival rate;
D O I
10.1016/S1386-6346(01)00184-X
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim of this study was to establish fucosylation index (H) of alpha-fetoprotein (AFP) before and after initial treatment as a useful prognostic factor in patients with hepatocellular carcinoma (HCC). One hundred ninety-seven patients with HCC from 1990 to 2000, in whom an increment of serum AFP concentrations more than 30 ng/ml was observed before treatment, were examined in the present study. Enrolled patients with HCC underwent transcatheter arterial embolization, chemoembolization, percutaneous ethanol injection and/or percutaneous microwave coagulation therapy. The current patients status was confirmed as of the end of March 2001. FI was determined by crossed immunoaffinoelectrophoresis in the presence of Lens culinaris agglutinin (LCA). F1 of AFP was defined as the percentage of the LCA-reactive species in total AFP (same as L3 fraction). When the tentative discriminating line of 171 was set at 18%, the mean survival rate in the HCC group, whose FI-1 (before treatment) was higher than 18% (high FI), was significantly lower than that in another HCC group, whose FI-1 was equal to or less than 18% (low FI) by the generalized Wilcoxon test and the log rank test (P<0.0001). There were statistical significant differences of survival rate when FI-2 (2 months after treatment) and FI-3 (at the time of HCC recurrence or 2 years after treatment in the case of no recurrence) were introduced in the same analysis. Additionally, statistical significant differences of survival rates were obtained between HCC groups with high and low FI-1 when the patient stage was limited to II, III, IVA or IVB. The HCC group, FI-1, FI-2 and FI-3 of which were persistently equal to or less than 18%, showed considerably better prognosis than the group, whose FI-1, FI-2 and FI-3 were persistently higher than 18%. The univariate analysis in the prognostic factor by the Cox's proportional hazards model showed that FI-1, FI-2 and FI-3 were independent prognostic factors. The present study indicates that measuring FI from the sera before and after the treatment serves as a new prognostic indicator and may improve prognostic estimates and appraisal of therapeutic outcome in patients with HCC. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:287 / 295
页数:9
相关论文
共 37 条
  • [1] ABELEV GI, 1968, CANCER RES, V28, P1344
  • [2] CARBOHYDRATE STRUCTURES OF HUMAN ALPHA-FETOPROTEIN OF PATIENTS WITH HEPATOCELLULAR-CARCINOMA - PRESENCE OF FUCOSYLATED AND NONFUCOSYLATED TRIANTENNARY GLYCANS
    AOYAGI, Y
    SUZUKI, Y
    IGARASHI, K
    SAITOH, A
    OGURO, M
    YOKOTA, T
    MORI, S
    SUDA, T
    ISEMURA, M
    ASAKURA, H
    [J]. BRITISH JOURNAL OF CANCER, 1993, 67 (03) : 486 - 492
  • [3] FUCOSYLATION OF SERUM ALPHA-FETOPROTEIN IN PATIENTS WITH PRIMARY HEPATOCELLULAR-CARCINOMA
    AOYAGI, Y
    ISEMURA, M
    YOSIZAWA, Z
    SUZUKI, Y
    SEKINE, C
    ONO, T
    ICHIDA, F
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1985, 830 (03) : 217 - 223
  • [4] AOYAGI Y, 1988, CANCER-AM CANCER SOC, V61, P769, DOI 10.1002/1097-0142(19880215)61:4<769::AID-CNCR2820610422>3.0.CO
  • [5] 2-M
  • [6] Aoyagi Y, 1998, CANCER, V83, P2076, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2076::AID-CNCR5>3.0.CO
  • [7] 2-L
  • [8] AOYAGI Y, 1985, LANCET, V2, P1353
  • [9] AOYAGI Y, 1984, JPN J CANCER RES, V75, P809
  • [10] MICROHETEROGENEITY OF ALPHA-FETOPROTEIN IN PATIENT SERUM AS DEMONSTRATED BY LECTIN AFFINO-ELECTROPHORESIS
    BREBOROWICZ, J
    MACKIEWICZ, A
    BREBOROWICZ, D
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1981, 14 (01) : 15 - 20